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We conducted a preliminary case–control investigation of the association of pancreatic
polypeptide (PP) with mild cognitive impairment (MCI) in 202 MCI cases (mean age,
81.6 years) and 202 age- and sex-matched cognitively normal controls in the Mayo
Clinic Study of Aging. Plasma PP was measured and examined as the natural logarithm
(continuous) and dichotomized at the median. The OR (95% CI) of MCI increased
with increasing PP [1.46 (1.04–2.05)]. There was a negative interaction of PP with
apolipoprotein E (APOE) ε4 allele; compared to the reference group (no APOE ε4 allele and
low PP), the OR (95% CI) for combinations of ε4 and PP were: 2.64 (1.39–5.04) for APOE
ε4 plus low PP; 2.09 (1.27–3.45) for no APOE ε4 plus high PP; and 1.91 (1.04–3.53)
for no APOE ε4 plus high PP (P for interaction=0.017). There was also a trend toward
a negative interaction with type 2 diabetes (P for interaction=0.058). Compared to no
diabetes and low PP, the OR (95% CI) was 3.02 (1.22–7.46) for low PP plus diabetes
but 1.80 (1.01–3.22) for high PP plus diabetes. Participants with high PP had a greater
mean (SD) weight loss (kilograms per decade) than persons with low PP [ 2.27 (4.07)
vs.  1.61 (5.24); P=0.016]. MCI cases had a non-significantly greater weight loss per
decade compared to controls. These findings suggest that high PP alone or jointly with
APOE ε4 allele or type 2 diabetes is associated with MCI, and that high PP may mitigate
some effects of APOE ε4 allele and type 2 diabetes on cognition. Potential mechanisms
may involve PP-related weight loss and centrally mediated effects of PP on cognition.
These findings remain to be validated in other studies.
Keywords: cognition, mild cognitive impairment, case–control study, pancreatic polypeptide, neuropeptide, type 2
diabetes, apolipoprotein E
Abbreviations: AD, Alzheimer’s disease; APOE, apolipoprotein E; BMI, body mass index; CF, cerebrospinal fluid; MCI, mild
cognitive impairment; MCSA, Mayo Clinic Study of Aging; PP, pancreatic polypeptide.
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Introduction
The need for diagnostic and prognostic biomarkers remains
essential for early detection and prevention of Alzheimer’s dis-
ease (AD). Blood-based (non-genetic) biomarkers are important
because they are easily acquired, relatively inexpensive compared
to brain imaging biomarkers, less invasive than cerebrospinal fluid
(CSF) acquisition, and more amenable to large-scale screening.
Blood-based biomarkers may have utility for early detection or
enhance recruitment and monitoring in clinical trials (Doecke
et al., 2012).
Pancreatic polypeptide (PP) has been associated with mild
cognitive impairment (MCI) and AD dementia in blood-based
biomarker panels for these conditions (Craig-Schapiro et al., 2011;
O’Bryant et al., 2011; Doecke et al., 2012). PP is produced by F
cells of the pancreatic islets of Langerhans and released into the
circulation after food ingestion. It is one of several neuropeptides
with activity both in the gut and in the brain regions affected
by AD dementia, such as the hippocampus, and hypothalamus
(Asakawa et al., 2003). The effects of secreted PP are mediated by
neuropeptide receptors (Y4 and Y5) in the brain and in the gut
through vagal signaling. In response to PP, there is vagal signaling
to neuroendocrine regions of the brain, such as the hypothalamus,
locus ceruleus, area postrema, dorsal vagal complex, and brain
stem regions that control gastrointestinal functions and regulate
food intake (Holzer et al., 2012; Asakawa et al., 2003; McTigue
et al., 1993). Physiologic effects of PP in response to vagal signal-
ing from the brain include decreased gastric emptying, appetite
suppression, decreased food intake, and a negative energy balance
(i.e., energy expenditure exceeds energy intake) (Asakawa et al.,
2003; Holzer et al., 2012). Low physiologic levels of PP and low
food-induced PP are associated with hyperphagia and morbid
obesity (Lassmann et al., 1980; Marco et al., 1980); in contrast,
administration of PP stimulates weight loss (Berntson et al., 1993).
Because of the association of high levels of PP with MCI and AD
dementia in biomarker panels usingmultiplex platforms, the asso-
ciation of high levels of PP with reduced food intake and weight
loss, and the importance of diet and caloric intake in risk of MCI
and AD, we hypothesized that abnormally increased PP levels
may be involved in the pathogenesis of MCI. The objective of this
study was to conduct a preliminary cross-sectional investigation
of plasma PP with MCI among participants in the Mayo Clinic
study of aging (MCSA).
Materials and Methods
Study Design and Participants
The details of the study design and methodology for participant
recruitment have been published (Roberts et al., 2008). Briefly,
the MCSA is a population-based study established in Olmsted
County, MN, USA, in 2004. Participants aged 70–89 years were
randomly selected from an enumeration of the county population
through the Rochester Epidemiology Project (Rocca et al., 2012),
a medical records linkage system. We excluded subjects who were
terminally ill or in hospice, or had previously diagnosed dementia.
Participants were clinically evaluated to assess cognitive status
(normal cognition, MCI, or dementia). Ongoing recruitment was
established in 2008 to maintain the sample size, and follow-up is
performed every 15months. All study protocols were approved
by the institutional review boards of the Mayo Clinic and Olm-
sted Medical Center. All participants provided written informed
consent prior to participation.
The clinical evaluation included an interview of the partici-
pant (using questions about memory) and an informant (using
the Functional Activities Questionnaire and Clinical Dementia
Rating Scale) (Pfeffer et al., 1982; Morris, 1993) by a study
coordinator to evaluate memory and functioning; a complete
neurologic evaluation by a physician, which included the Short
Test of Mental Status – a global test of memory (Kokmen et al.,
1987) and a full neurological evaluation; and a neuropsychological
testing battery consisting of nine tests to assess performance in
four cognitive domains: memory (three tests), executive func-
tion (two tests), visuospatial skills (two tests), and language (two
tests) (Roberts et al., 2008; Petersen et al., 2010). Data from
the evaluation were reviewed for a diagnosis of MCI defined
as: (i) cognitive concern; (ii) impairment in one or more cog-
nitive domains; (iii) essentially normal functional activities; and
(iv) absence of dementia (Petersen, 2004; Roberts et al., 2008;
Petersen et al., 2009, 2010), taking into account level of educa-
tion and longest held occupation. A diagnosis of dementia was
based on DSM IV criteria (American Psychiatric Association,
2000; Petersen, 2004; Roberts et al., 2008; Petersen et al., 2009,
2010); diagnosis of normal cognition was made in persons who
performed in the normal cognitive range and did not meet cri-
teria for MCI or dementia (Roberts et al., 2008; Petersen et al.,
2010).
MCI Cases and Controls
Cases and controls for the present studywere selected from among
participants who were evaluated prior to December 31, 2011,
and had stored blood samples available for measurement of PP.
Among 1,323 eligible participants, 202 had MCI. Each case was
matched to a cognitively normal control by sex, age (2 years),
number of clinical visits in the MCSA (1), and duration of
follow-up (1 year; 1:1 matching).
Measurement of PP
Pancreatic polypeptide was measured using a radioimmunoassay
technique developed in the Mayo Clinic Endocrine Laboratory
(Schwartz, 1983; Koch et al., 1985) The assay included a com-
mercial antibody from Peninsula Laboratories International, Inc.,
radioactive reagents from PerkinElmer Inc., and calibrationmate-
rial from Sigma-Aldrich. The assay system utilized rabbit antihu-
man PP antiserum, a standard or patient plasma specimen, and
radiolabeled human PP, which has been iodinated by a modified
Hunter–Greenwood technique. The sample and antibody (both
primary and secondary) and the radioactive label were diluted
in the same buffer. The buffer consisted of 0.02M sodium 5,5-
diethylbarbiturate (Sigma B-050), 4.12 g, 0.006M barbituric acid
(Fisher CAS#67527), 0.02% bovine serum albumin and some
preservatives dissolved in water, and the pH was adjusted to
8.2. The buffer and precipitating antibody and validation were
performed in the laboratory. The standard (patient) HPP com-
petes with the radioactive HPP for binding sites on the primary
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antibody, which is rabbit anti-human pancreatic polypeptide.
This antibody complex was precipitated with Goat Anti Rabbit
serum along with normal rabbit serum and polyethylene glycol.
The mixture was centrifuged and the supernate discarded. The
radioactive counts in the pellet are inversely proportional to the
amount of HPP present in the tube. The 2.5 SD detection limit
based on 20 determinations from one assay was 28.5 pg/mL. The
coefficients of variation were 3.65% for intra-assay precision and
8.05% for interassay precision.
Other Covariates
Demographic variables were assessed at baseline by interview.
Medical comorbidities (type 2 diabetes mellitus, hypertension,
stroke, and coronary artery disease) and maximum adult weight
(age 40–65 years) were ascertained from medical records of
each participant using the Rochester Epidemiology Project.
Apolipoprotein E (APOE) genotyping was performed from a
blood draw using standard methods (Hixson and Vernier, 1990),
and depressive symptoms were ascertained from the Neuropsy-
chiatric Inventory Questionnaire (Kaufer et al., 2000).
Statistical Analyses
The distribution of PP in cases and controls was skewed, so we
characterized PP using the natural logarithm. We also exam-
ined PP as a dichotomous variable, with a high PP (consid-
ered abnormal) arbitrarily defined using a median split and the
90th percentile based on the distribution of PP levels for cog-
nitively normal controls. We examined the associations of PP
with MCI using conditional logistic regression models matched
on sex and age (basic model) and also adjusted for age at
sample draw to account for any residual confounding by age.
In separate models, we investigated potential confounding of
the association of PP with MCI by covariates that were sig-
nificantly associated with MCI [education, depression, hyper-
tension, coronary artery disease, type 2 diabetes, and APOE
ε4 genotype (any ε4 vs. no ε4 allele)]; there was no associa-
tion with body mass index (BMI). We examined effect modi-
fication by including interaction terms of each covariate with
PP (dichotomized as median vs. >median) in models with
the main effects. To determine whether PP was associated with
weight loss prior to the date of blood draw, we computed the
average weight loss (in kilograms) per decade from the max-
imum weight in midlife to date of blood draw for PP assess-
ment in MCI cases vs. controls and for participants with high
vs. low PP levels. Comparisons across groups were made using
Wilcoxon rank sum tests. All P values were considered significant
at alpha of 0.05. Analyses were performed by SAS version 9.3
(SAS Institute).
Results
The characteristics of MCI cases and controls are described in
Table 1. The mean age was 81.6 years and 58.9% were men. Cases
had significantly fewer years of education; higher frequency of
type 2 diabetes, hypertension, coronary artery disease, depressive
symptoms, and APOE ε4 allele status; and marginally higher PP
levels compared to controls (P= 0.073).
TABLE 1 | Characteristics of study participants.
Characteristic Normal cognition
(N=202)
MCI
(N=202)
Male sex, no. (%) 119 (58:9) 119 (58:9)
Age, mean (SD) (years) 81:6 (5:8) 81:6 (5:8)
Education, mean (SD) (years)a 14:4 (2:8) 13:7 (3:0)
APOE ε4 allele, no. (%)b 54 (26:7) 70 (34:7)
BMI, mean (SD) 27:2 (4:3) 27:2 (4:8)
Diabetes, no. (%)a 39 (19:3) 59 (29:2)
Hypertension, no. (%)a 158 (78:2) 174 (86:1)
Coronary artery disease, no. (%)a 66 (32:7) 88 (43:6)
Depressive symptoms, no. (%)a 11 (5:4) 23 (11:4)
PP
Median PP (IQR)b 196 (141:0; 308:0) 229 (148:0; 343:0)
Ln PP median (IQR)b 5:28 (4:95; 5:73) 5:43 (5:00; 5:84)
>50th percentile (median), no. (%)b 100 (49:8) 119 (59:2)
>90th percentile, no. (%)b 20 (10:0) 32 (15:9)
BMI, body mass index; IQR, interquartile range; ln, natural logarithm; MCI, mild cognitive
impairment; PP, pancreatic polypeptide.
Percentages are based on non-missing numbers.
aP 0.05.
b0.05<P< 0.10.
Pancreatic polypeptide level was missing in one control and one case.
TABLE 2 | Conditional logistic regression models for association of
pancreatic polypeptide with mild cognitive impairment.
Model 1a
β (SE) OR (95% CI) P value
Ln PP 0.379 (0.173) 1.46 (1.04–2.05) 0.029
PP>medianb 0.388 (0.214) 1.47 (0.97–2.24) 0.069
PP>90th percentilec 0.637 (0.327) 1.89 (1.00–3.59) 0.051
ln, natural logarithm; PP, pancreatic polypeptide.
aModel 1: Conditional logistic regression models adjusted for education. Participants were
matched on age and sex.
bMedian PP, 196pg/mL.
c90th percentile, 452 pg/mL.
Cross-Sectional Association of PP with MCI
In age- and sex-adjusted models, the OR of MCI increased
with increasing PP level [β (SE), 0.379 (0.173); P= 0.029]
(Table 2). When participants were characterized by dichotomous
cut points, the associations of high PP with MCI persisted but
were marginally significant: OR, 1.47 (P= 0.069) for PP greater
than median and OR, 1.89 (P= 0.051) for PP >90th percentile
(Table 2). There was no confounding by coronary artery disease,
type 2 diabetes, hypertension, depressive symptoms, or APOE ε4
allele when each variable was separately included in a model with
age and sex (data not shown). When all the potential confounders
were included in the model, the OR for MCI remained elevated
but decreased to 1.33 (P= 0.116).
We observed a significant interaction of PPwithAPOE ε4 allele
(P for interaction= 0.017). The joint effects of high PP and APOE
ε4 allele were indicative of a negative (antagonistic) interaction.
Compared to the reference group (no APOE ε4 allele and low
PP), the ORs (95% CIs) for combinations of APOE and PP were
as follows: 2.64 (1.39–5.04), P= 0.003 for APOE ε4 plus low PP;
2.09 (1.27–3.45), P= 0.004 for no APOE ε4 plus high PP; and 1.91
(1.04–3.53), P= 0.038 for APOE ε4 plus high PP (Figure 1). There
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FIGURE 1 | Interaction of pancreatic polypeptide (PP) with APOE ε4
Allele. Compared to persons without an APOE ε4 allele and low PP level
(reference), the ORs (95% CIs) were as follows: 2.64 (1.39–5.04), P= 0.003
for low PP plus APOE ε4 allele; 2.09 (1.27–3.45), P= 0.004 for high PP
without APOE ε4 allele; and 1.91 (1.04–3.53), P= 0.038 for high PP plus
APOE ε4 allele. PP was dichotomized at the median as low PP (196pg/mL)
and high PP (>196pg/mL).
FIGURE 2 | Interaction of pancreatic polypeptide (PP) with type 2
diabetes. Compared to persons without type 2 diabetes and low PP level
(reference), the ORs (95% CIs) were as follows: 3.02 (1.22–7.46), P= 0.017
for low PP plus diabetes; 1.69 (1.07–2.68), P= 0.026 for high PP without
diabetes; and 1.80 (1.01–3.22), P= 0.046 for high PP plus diabetes. PP was
dichotomized at the median as low PP (196pg/mL) and high PP
(>196pg/mL).
was also amarginal negative interactionwith type 2 diabetes (P for
interaction= 0.058). Compared to the reference group (no type
2 diabetes and low PP), the ORs (95% CIs) of MCI were: 3.02
(1.22–7.46), P= 0.017 for diabetes plus low PP; 1.69 (1.07–2.68),
P= 0.026 for no diabetes plus high PP; and 1.80 (1.01–3.22),
P= 0.046 for diabetes plus high PP (Figure 2).
Weight Loss
Mild cognitive impairment cases had a non-significantly greater
mean (SD) weight loss (kilograms per decade) assessed from
midlife to date of blood draw for measurement of PP compared
to controls [ 2.40 (5.14) vs.  1.53 (4.03); P= 0.124]. However,
participants with high PP had a greater mean weight loss per
decade than persons with low PP [ 2.27 (4.07) vs.  1.61 (5.24);
P= 0.016] and a non-significantly lower BMI [26.906 (4.73) vs.
27.534 (4.37); P= 0.212].
Discussion
In this preliminary case–control study of elderly persons, elevated
PP levels were associated with an increased OR of MCI. However,
the association of PP with MCI varied significantly by APOE ε4
allele, and non-significantly, by diabetes status. High PP was also
associated with greater weight loss per decade, and MCI cases
had a non-significantly greater weight loss per decade compared
to controls. The findings suggest that PP may be involved in
the pathogenesis of MCI and should be examined in a definitive
prospective study.
The negative interaction of PP with APOE ε4 allele and
marginally significant interaction with diabetes are interesting,
but the implications are unclear. The interactions showed that
the OR for the joint effects of an APOE ε4 allele or diabetes
with high PP was lower than that for APOE ε4 or diabetes with
low PP (i.e., APOE ε4 or diabetes alone), but comparable to the
elevated estimates of OR in APOE ε4 allele non-carriers and in
non-diabetics.
Our findings are in keeping with findings from other investi-
gators (Doecke et al., 2012; Hu et al., 2012; Soares et al., 2012;
O’Bryant et al., 2013; Burnham et al., 2014). In the Australian
Imaging Biomarker and Lifestyle study, PP levels were elevated
1.54-fold in AD dementia cases compared to cognitively normal
controls (Doecke et al., 2012). In AD Neuroimaging Initiative
samples/cohorts plasma, PP levels were higher in AD dementia or
MCI cases compared to controls (Kiddle et al., 2012; Soares et al.,
2012). In the Texas Alzheimer’s Research and Care Consortium,
PP was overexpressed in a biomarker panel and improved the
diagnostic accuracy for AD in whites (O’Bryant et al., 2011) and
inMexican Americans (O’Bryant et al., 2013). In two independent
samples from the University of Pennsylvania and Washington
University, elevated PP levels were associated with impaired cog-
nition (MCI, AD dementia, or Clinical Dementia Rating of 0.5 or
1) (Hu et al., 2012).
Mechanisms that mitigate effects of elevated PP levels on
MCI risk in APOE ε4 carriers may involve the need to
maintain a balance in inhibitory and excitatory input in
the hippocampus for memory encoding and spatial recogni-
tion (Andrews-Zwilling et al., 2010). This balance is main-
tained by somatostatin-expressing cells, which colocate with
γ-aminobutyric acid-ergic (GABAergic) expression to provide
inhibitory input on pyramidal cell activity in the hippocampus
(Freund and Buzsaki, 1996). With aging, there is a decrease
in somatostatin and GABAergic interneuron expression in the
hippocampus; this results in increased excitatory activity at rest
that is hypothesized to contribute to memory impairment in
amnestic MCI (Yassa et al., 2010, 2011). This decreased somato-
statin expression is also observed in AD brains and in APOE ε4
allele carriers (Kumar, 2005). Functional imaging studies have
reported greater default brain network activation at rest and dur-
ing memory tasks and greater hippocampal activation in persons
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at increased risk of genetic or familial AD, APOE ε4 allele carriers
(Bookheimer et al., 2000; Bassett et al., 2006; Filippini et al., 2009),
and in individuals with MCI (Dickerson et al., 2004, 2005; Celone
et al., 2006; Hamalainen et al., 2007). These findings suggest that
there is increased imbalance in inhibitory–excitatory signals and
impaired inhibition of GABAergic interneurons in persons at risk
for AD, such as persons with MCI and ε4 carriers. This APOE ε4
effect may be exacerbated in elderly ε4 carriers who also have age-
related decrease in somatostatin, resulting in greater excitatory
activity in granule and pyramidal cells in the hippocampal forma-
tion and impaired memory encoding compared to non-carriers
(Andrews-Zwilling et al., 2010). In aMCI patients, administra-
tion of antiepileptic drugs reduced CA3/dentate overactivity and
improved memory performance (Bakker et al., 2012).
Similarly, animal studies have demonstrated decreased
somatostatin in mouse models of age-related neurodegeneration
(Andrews-Zwilling et al., 2010) and in the CA3/dentate gyrus
of aged rats with age-related loss of spatial memory involving
the hippocampus (Spiegel et al., 2013). A recent study in mice
demonstrated that PP activates somatostatin-expressing cells
in the hippocampus (Kim et al., 2014). Other animal studies
have also reported beneficial effects of antiepileptic drugs and
inhibitory neuropeptides that target loss of GABAergic activity
on memory performance in memory-impaired rats compared to
controls (Koh et al., 2010, 2013). APOE ε4 impairs GABAergic
interneurons, increases excitatory activity in the hippocampus,
and impairs memory encoding (Andrews-Zwilling et al., 2010).
Pentobarbital was observed to improve performance in APOE ε4
knock-in mice with deficits in hippocampal inhibitory activity
(Andrews-Zwilling et al., 2010). Together, these human and
animals studies are highly relevant to our findings and are in
keeping with the interaction of PP with APOE ε4 allele observed
in our study. If indeed PP (a neuropeptide) activates somatostatin-
containing cells in persons at risk for AD (e.g., APOE ε4 carriers),
elevated levels of PP in APOE ε4 carriers may reduce excitatory
signals, reduce the inhibitory–excitatory imbalance to GABAergic
neurons, and promote memory encoding.
In persons with diabetes, elevated PP levels may reduce the
likelihood of MCI by effects on weight reduction, negative energy
balance, and improved glycemic control. Effects of PP are medi-
ated by binding to neuropeptide Y (NPY) receptors in the gas-
trointestinal tract, pancreas, liver, and brain (hippocampus and
hypothalamus). High PP levels may increase insulin secretion
from the pancreatic islets of Langerhans cells through inhibition
of somatostatin release (Mandarino et al., 1981; D’Alessio et al.,
1989; Kim et al., 2014). Elevated levels of PP secretion observed
in diabetics (Floyd et al., 1976) is hypothesized to be a com-
pensatory mechanism to increase insulin release and improve
glycemic control (Floyd et al., 1976; Kim et al., 2014); this may
also enhance brain insulin signaling and glucose metabolism, and
thereby reduce MCI risk (Roberts et al., 2013). Central effects
of PP involve the hypothalamus, dorsal vagal complex (McTigue
et al., 1993). High circulating PP may enhance the brain control
of gastrointestinal functions (McTigue et al., 1993; Asakawa et al.,
2003). PP inhibits hypothalamic release of neuropeptides that
stimulate eating, enhances release of anorexigenic hypothalamic
peptides, and suppresses gastric release of ghrelin (an appetite
stimulant) (Asakawa et al., 2003), with potentially beneficial
effects in diabetics.
In APOE ε4 non-carriers and non-diabetics, the potential
mechanisms for the association of high PP levels with MCI are
unclear, but may relate to dietary effects of PP. Overexpression
of PP may lead to decreased food intake, excessive weight loss,
anemia, and deficiencies in micronutrients required for neuronal
function. Consistent with this, we observed a non-significantly
greater weight loss per decade inMCI cases compared to controls,
in keeping with reported declines in weight prior to dementia
(Nourhashemi et al., 2003; Knopman et al., 2007; Besser et al.,
2014; Sobow et al., 2014). Persons with high PP levels in the
study also had a greater average weight loss and lower BMI
than persons with lower PP levels. Nutritional deficiencies have
adverse implications for cognition. Several dietary nutrients and
antioxidants including vitamins (e.g., A, C, D, E, folate, B12),
monounsaturated and polyunsaturated fatty acids, dietary antiox-
idants, and phospholipids (Blok et al., 1996; Engelhart et al., 2002;
Chrysohoou et al., 2004; Feart et al., 2009; Roberts et al., 2010a,b)
are beneficial for cognitive function. Deficiencies in micronutri-
ents reportedly occur prior to the protein-calorie malnutrition
observed in patients with AD dementia (Lopes da Silva et al.,
2014). Dietary nutrients are the basis for ongoing AD dementia
prevention and treatment trials (Scheltens et al., 2010; Hartmann
et al., 2014; Swaminathan and Jicha, 2014). Elevated PP levels have
been observed in persons with both AD and non-AD dementia
(Hu et al., 2012). The association with non-AD dementia, which
may have a vascular etiology, suggests that vascular mechanisms,
possibly involving diet-related metabolic or signaling abnormal-
ities, may be involved in the association of PP with cognitive
impairment. There are also suggestions that elevated PP levelsmay
be part of an immune signature that may adversely affectMCI risk
(Hallgren and Lundqvist, 1980; Ray et al., 2007; Burnham et al.,
2014).
The cause of the abnormally elevated levels of PP is uncertain.
There are suggestions that this could result from a dysfunction
in cholinergic tone that precedes and is present in clinical AD
dementia (Mufson et al., 2008; Doecke et al., 2012; Hu et al., 2012;
Soares et al., 2012; O’Bryant et al., 2013; Burnham et al., 2014).
Elevated levels of PP observed in CSF of patients with AD suggest
that impaired transport across the blood–brain and CSF barriers
may occur (Hu et al., 2010, 2012). A disruption in the blood–brain
barrier in the aging hippocampus could also lead to elevated brain
PP levels (Hu et al., 2012; Montagne et al., 2015).
A limitation of our study is that the case–control design pre-
cludes our ability to assess causality. However, these preliminary
findings have generated hypotheses for further investigations.
Another limitation is that several gut hormones that influence
energy balance may interact with PP; however, as an initial step,
we specifically examined only PP. Another limitation is that due
to the imbalance in MCI risk factors between cases and controls,
the ORs were attenuated in the multivariable models and the
associations were no longer significant. Finally, several complex
metabolic and neuronal pathways and mechanisms are involved
in the association of PP with cognition and we are limited in our
ability to fully investigate these associations using a case–control
design.
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Our study has several strengths. Participants were well
characterized for cognitive outcomes. We adjusted for the
effects of vascular risk factors using information from the
medical record. In contrast to several studies, we measured
PP levels from overnight fasting blood samples to eliminate
potential confounding by food intake. Given the prospective
design of the MCSA, we are able to conduct a definitive
study to test the hypotheses generated by this preliminary
investigation.
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